HBM Holdings Limited (2142.HK)

1,380 -0,020 (-1,43%) Al cierre: 04:08PM HKT

HBM Holdings Limited

Building A3
Suite 202 218 Xinghu Street Suzhou Industrial Park
Suzhou 215123
China
86 51 2657 90025
https://www.harbourbiomed.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 177

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jingsong Wang M.D., Ph.D.	Founder, Chairman & CEO	7,24M	N/A	1965
Dr. Yiping Rong Ph.D.	Chief Scientific Officer & Executive Director	3,05M	N/A	1978
Mr. Weihao Xu	CFO, Chief Business Officer and Global Head of Business & Corporate Development	N/A	N/A	1983
Mr. Bruce Zhang	Head of Legal	N/A	N/A	N/A
Dr. Peter F. Moesta Ph.D.	Member of Scientific Advisory Board & Chief CMC Advisor	N/A	N/A	N/A
Dr. Xiaolu Tao	Chief Development Officer	N/A	N/A	1974
Dr. Steve Arkinstall DPhil	Chief Scientific Advisor	N/A	N/A	N/A
Mr. Wing Yat Lui	Company Secretary	N/A	N/A	1990

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7. The company is also developing HBM9378 for the treatment of Asthma; and HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaborations with AstraZeneca, Pfizer, Hualan Genetic Engineering Co., Ltd., Beigene, Ltd., Duality Biotherapetuics, Inc., Mythic Therapeutics, Washington University, Evive Biotech. HBM Holdings Limited was incorporated in 2016 and is based in Suzhou, the People's Republic of China.

Gobierno corporativo

El ISS Governance QualityScore de HBM Holdings Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.